Skip to main content

Alnylam market cap gains billions on results of heart drug trial

Alnylam Pharmaceuticals Inc. said Wednesday morning that a 12-month trial of one of its RNA-blocking drugs met its primary goal, propelling its stock up more than 50% in pre-market trading. The Cambridge-based drugmaker said the late-stage study of patisiran showed it did significantly better than a placebo in treating patients with an increasingly common heart condition.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.